BLOG

AACR: FUSION PROTEIN SO-C101 WITH PEMBRO IN ADULT PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS

Sotio is developing an IL-15 superagonist, SO-C101, as a potent immunotherapy for patients with cancer. This study examined SO-C101 in multiple tumor mouse models alone and in combination with PD-1 inhibition.